KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Capital Expenditures (2016 - 2025)

Idexx Laboratories has reported Capital Expenditures over the past 17 years, most recently at $29.4 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $29.4 million for Q4 2025, down 73.37% from a year ago — trailing twelve months through Dec 2025 was $124.7 million (up 3.1% YoY), and the annual figure for FY2025 was $124.7 million, up 3.1%.
  • Capital Expenditures for Q4 2025 was $29.4 million at Idexx Laboratories, down from $31.1 million in the prior quarter.
  • Over the last five years, Capital Expenditures for IDXX hit a ceiling of $129.2 million in Q4 2022 and a floor of -$21.5 million in Q2 2022.
  • Median Capital Expenditures over the past 5 years was $22.3 million (2024), compared with a mean of $32.4 million.
  • Biggest five-year swings in Capital Expenditures: plummeted 797.08% in 2022 and later skyrocketed 1393.71% in 2025.
  • Idexx Laboratories' Capital Expenditures stood at $104.8 million in 2021, then rose by 23.24% to $129.2 million in 2022, then plummeted by 74.8% to $32.6 million in 2023, then surged by 239.47% to $110.5 million in 2024, then tumbled by 73.37% to $29.4 million in 2025.
  • The last three reported values for Capital Expenditures were $29.4 million (Q4 2025), $31.1 million (Q3 2025), and $53.4 million (Q2 2025) per Business Quant data.